Remove Drug Trials Remove Therapies Remove Treatment
article thumbnail

Recombinant polyclonal drug trial for HBV gets FDA green light

Drug Discovery World

The US Food and Drug Administration (FDA) has cleared GigaGen’s application to initiate a Phase I trial of its polyclonal drug for the treatment of hepatitis B virus (HBV) infection, GIGA-2339. With over 1,000 different HBV-targeted antibodies in the mixture, GIGA-2339 is unlike any therapy currently in development.

article thumbnail

First patient dosed in ulcerative colitis drug trial

Drug Discovery World

A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). These patients will be randomised to treatment with intravenous ExoFlo every month or every other month over the course of one year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

This week in drug discovery (5-9 August) 

Drug Discovery World

The news highlights this week all centre around significant US Food and Drug Administration (FDA) regulatory decisions, including new approvals for drugs for solid tumours, hepatitis B and glioma.

FDA 130
article thumbnail

Six advances in drug discovery for MND / ALS

Drug Discovery World

Ahead of Motor Neurone Disease (MND) Awareness Day on 21 June, we take a look back over the latest developments in the treatment of MND and amyotrophic lateral sclerosis (ALS). A new UK research partnership In June, UK charity LifeArc pledged £1.5

article thumbnail

This week in drug discovery (30 Oct-3 Nov)  

Drug Discovery World

News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist.

article thumbnail

Mathematical model can speed up Alzheimer’s drug development

Drug Discovery World

Researchers have created a mathematical model that can accurately depict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. These findings closely matched the results of the corresponding real-life clinical trials.

article thumbnail

This week in drug discovery (6-10 February)

Drug Discovery World

Clinical drug trials have made the headlines this week, as it was revealed that breast cancer still tops the bill for number of clinical studies and the shortcomings in current methods to ensure representation of patient populations in trials were exposed.